Home/Pipeline/NeuroSTAT® (OWL-1410)

NeuroSTAT® (OWL-1410)

Traumatic Brain Injury (TBI)

Pre-clinicalActive

Key Facts

Indication

Traumatic Brain Injury (TBI)

Phase

Pre-clinical

Status

Active

Company

Owl Therapeutics

About Owl Therapeutics

Owl Therapeutics is a private, preclinical-stage biotech pioneering a novel approach to neurological diseases by focusing on microglial enhancement. Its core strategy combines a proprietary generative AI platform for drug design with biomarker-driven precision medicine to increase development efficiency. The company has established key partnerships, including a licensing and clinical collaboration with Abliva for NeuroSTAT® in TBI, and is led by a team with deep experience from major biopharma firms like Genentech. Owl is positioning itself at the intersection of AI-driven drug discovery and the high-need neuroimmunology space.

View full company profile

Therapeutic Areas

Neurology Neurodegenerative Diseases Traumatic Brain Injury

Other Traumatic Brain Injury (TBI) Drugs

Drug	Company	Phase	Status
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IQool™ System	BrainCool	Clinical Evaluation	Investigational
Unnamed programs	Astrocyte Pharmaceuticals	Preclinical	Research stage
MAP4343	Mapreg	Preclinical	Active
LG3	Stream Biomedical	Pre-clinical	Active
MTR® for Traumatic Brain Injury	Renovo Concepts	Phase 1	Active
Autologous Wnt-activated ADSC Therapy	Regeneration Biomedical	Pre-clinical	Active
IRRAflow System	IRRAS	Clinical Evaluation	Active